DK148480C - Analogifremgangsmaade til fremstilling af cycloalkyltriazoler - Google Patents

Analogifremgangsmaade til fremstilling af cycloalkyltriazoler

Info

Publication number
DK148480C
DK148480C DK156779A DK156779A DK148480C DK 148480 C DK148480 C DK 148480C DK 156779 A DK156779 A DK 156779A DK 156779 A DK156779 A DK 156779A DK 148480 C DK148480 C DK 148480C
Authority
DK
Denmark
Prior art keywords
cyctrizoles
cycloal
preparation
analogy procedure
analogy
Prior art date
Application number
DK156779A
Other languages
Danish (da)
English (en)
Other versions
DK156779A (da
DK148480B (da
Inventor
Bruno Silvestrini
Leandro Baiocchi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of DK156779A publication Critical patent/DK156779A/da
Publication of DK148480B publication Critical patent/DK148480B/da
Application granted granted Critical
Publication of DK148480C publication Critical patent/DK148480C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK156779A 1978-04-18 1979-04-17 Analogifremgangsmaade til fremstilling af cycloalkyltriazoler DK148480C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT22421/78A IT1094076B (it) 1978-04-18 1978-04-18 Cicloalchiltriazoli
IT2242178 1978-04-18

Publications (3)

Publication Number Publication Date
DK156779A DK156779A (da) 1979-10-19
DK148480B DK148480B (da) 1985-07-15
DK148480C true DK148480C (da) 1985-12-16

Family

ID=11196066

Family Applications (1)

Application Number Title Priority Date Filing Date
DK156779A DK148480C (da) 1978-04-18 1979-04-17 Analogifremgangsmaade til fremstilling af cycloalkyltriazoler

Country Status (22)

Country Link
US (2) US4252721A (it)
JP (1) JPS5817757B2 (it)
AT (1) AT374477B (it)
AU (1) AU520788B2 (it)
BG (2) BG40654A3 (it)
CA (1) CA1104567A (it)
CH (1) CH639847A5 (it)
DE (1) DE2915318A1 (it)
DK (1) DK148480C (it)
FI (1) FI66378C (it)
FR (1) FR2423221A1 (it)
GB (1) GB2020269B (it)
HU (1) HU179917B (it)
IE (1) IE47965B1 (it)
IL (1) IL56926A (it)
IT (1) IT1094076B (it)
NL (1) NL186635C (it)
PL (1) PL116103B1 (it)
PT (1) PT69502A (it)
SE (1) SE437663B (it)
SU (1) SU852174A3 (it)
YU (1) YU41338B (it)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
FR2580648B1 (fr) * 1985-04-17 1987-05-15 Adir Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4879294A (en) * 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
IT1224250B (it) * 1988-06-10 1990-09-26 Acraf Associzione del depiprazolo con la morfina
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US6187774B1 (en) 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
KR100639543B1 (ko) 1998-09-30 2006-10-31 다케다 야쿠힌 고교 가부시키가이샤 방광 배출력 개선제
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
EP1410808A4 (en) * 2001-07-02 2009-07-29 Santen Pharmaceutical Co Ltd MEDIUM FOR THE PROTECTION OF THE SEHNERV WITH ALPHA 1 RECEPTOR BLOCKER AS AN ACTIVE SUBSTANCE
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CA2526730A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
EP1863484A1 (en) * 2005-03-21 2007-12-12 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
ES2313626T3 (es) * 2005-03-21 2009-03-01 Pfizer Limited Derivados de triazol sustituidos como antagonistas de oxitocina.
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
BRPI0714361A2 (pt) * 2006-07-14 2013-03-26 Ranbaxy Lab Ltd polimorfo cristalino, composiÇço farmacÊutica contendo o mesmo, mÉtodo para sua preparaÇço e mÉtodo de tratamento
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
KR20210096096A (ko) 2018-10-26 2021-08-04 오큐파이어 파마, 인크. 노안, 산동, 및 기타 안구 장애의 치료를 위한 방법 및 조성물
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913454A (en) * 1956-11-23 1959-11-17 Schenley Ind Inc Certain cycloalkanotriazoles, process and intermediates
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3472853A (en) * 1967-05-29 1969-10-14 Sterling Drug Inc 1-((pyrido(2,1-c)-s-triazolyl)-lower-alkyl)-4-substituted- piperazines
JPS5070389A (it) * 1973-10-30 1975-06-11

Also Published As

Publication number Publication date
PL116103B1 (en) 1981-05-30
SE7903327L (sv) 1979-10-19
AT374477B (de) 1984-04-25
US4307095A (en) 1981-12-22
AU520788B2 (en) 1982-02-25
FR2423221B1 (it) 1983-03-18
CH639847A5 (it) 1983-12-15
IE790646L (en) 1979-10-18
YU41338B (en) 1987-02-28
FI791217A (fi) 1979-10-19
AU4583279A (en) 1979-10-25
PL214969A1 (it) 1980-03-10
YU86279A (en) 1983-12-31
PT69502A (en) 1979-05-01
IE47965B1 (en) 1984-08-08
BG61367B2 (bg) 1997-06-30
IT7822421A0 (it) 1978-04-18
IL56926A (en) 1983-09-30
GB2020269A (en) 1979-11-14
DK156779A (da) 1979-10-19
IL56926A0 (en) 1979-05-31
IT1094076B (it) 1985-07-26
DE2915318C2 (it) 1990-12-13
HU179917B (en) 1983-01-28
SU852174A3 (ru) 1981-07-30
SE437663B (sv) 1985-03-11
BG40654A3 (en) 1987-01-15
DK148480B (da) 1985-07-15
DE2915318A1 (de) 1979-10-31
US4252721A (en) 1981-02-24
CA1104567A (en) 1981-07-07
FR2423221A1 (fr) 1979-11-16
FI66378C (fi) 1984-10-10
ATA292479A (de) 1983-09-15
JPS5817757B2 (ja) 1983-04-09
JPS54157576A (en) 1979-12-12
FI66378B (fi) 1984-06-29
NL7902489A (nl) 1979-10-22
GB2020269B (en) 1982-06-03
NL186635C (nl) 1991-01-16
NL186635B (nl) 1990-08-16

Similar Documents

Publication Publication Date Title
DK148480C (da) Analogifremgangsmaade til fremstilling af cycloalkyltriazoler
DK325079A (da) Fremgangsmaade til fremstilling af tiazolidinderivater
DK365079A (da) Fremgangsmaade til fremstilling af 1-alfa-hydroxylerede calciferoler
DK153540C (da) Analogifremgangsmaade til fremstilling af platin-diamin-komplekser
DK129879A (da) Fremgangsmaade til fremstilling af n-heterocyclyl-4-piperidinaminer
DK158225C (da) Analogifremgangsmaade til fremstilling af carbostyrilderivater
DK68179A (da) Fremgangsmaade til fremstilling af 9-aminodibenzoepyraner
DK77479A (da) Fremgangsmaade til fremstilling af penicilliner
DK268579A (da) Fremgangsmaade til fremstilling af phenetamolaminer
DK307279A (da) Fremgangsmaade til fremstilling af phenolethere
DK69479A (da) Fremgangsmaade til fremstilling af 2-phenylimino-imidazolidiner
DK265779A (da) Fremgangsmaade til fremstilling af o-methallyloxyphenol
DK433779A (da) Fremgangsmaade til fremstilling af phenylquinolizidiner
DK150471C (da) Fremgangsmaade til fremstilling af trifluormethylphenoler
DK543079A (da) Fremgangsmaade til fremstilling af benzaldehyder
DK149748C (da) Analogifremgangsmaade til fremstilling af n-phenethylacetamidforbindelser
DK58579A (da) Fremgangsmaade til fremstilling af hydroxyphenylethere
DK154926C (da) Fremgangsmaade til fremstilling af en etomidatholdig infusionsvaeske
DK145179A (da) Fremgangsmaade til fremstilling af 4-methyl-5-hydroxymethyl-imidazol
DK282379A (da) Fremgangsmaade til fremstilling af phenylpiperidinderivater isaer substituerede eventuelt enkeltmaettede 1-benzylphenylpiperidiner
DK165325C (da) Analogifremgangsmaade til fremstilling af 4-aza-17-substituerede 5alfa-androstan-3-oner
DK239279A (da) Fremgangsmaade til fremstilling af 2-oximinophenylacetonitril
DK185179A (da) Fremgangsmaade til fremstilling af 3-halogen-2-hydroxyalkyltrialkylammoniumunchlorider
DK486079A (da) Fremgangsmaade til fremstilling af dihydroxysteroider
DK157017C (da) Analogifremgangsmaade til fremstilling af carbostyrilderivater

Legal Events

Date Code Title Description
PBP Patent lapsed
PBP Patent lapsed